As the year comes to a close, we revisit some of this year’s top content on next-generation imaging.
There’s been an abundance of news surrounding imaging agents in the urologic space over the past year. In light of all the progress that’s been made, Urology Times® is counting down the top pieces of content on next-generation imaging in 2022.
“We all recognize it’s better than conventional imaging in terms of finding metastatic lesions and with that, it enables us to grow our potential patient basefor targeted therapies,” David Morris, MD. Watch now.
Leonard S. Marks, MD, explained how the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer will affect urologists and patients alike. Watch now.
Over 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) who received the PSMA-targeted therapy 225Ac-PSMA-617 had a 50% or greater reduction in their PSA level, according to study findings published online in The Journal of Nuclear Medicine. Read more.
The FDA authorized the launch of the phase 1/2 COBRA trial exploring the novel PSMA-PET imaging agent 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy. Read more.
“We now have convincing evidence that these tests help identify more sites of prostate cancer," said Michael Leapman, MD. Read more.
The FDA approved the targeted radioligand therapy 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto)for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting. Read more.
Novartis announced in a news release that it resumed production of 177Lu-PSMA-617, along with screening and enrollment for all global clinical trials of the targeted radioligand therapy. Read more.
Richard Wahl, MD, discussed the approval of the targeted radioligand therapy 177Lu-PSMA-617for the treatment of patientswith PSMA-positive metastatic castration-resistant prostate cancer and the significance of Lu 177 vipvotide tetraxetan in the prostate cancer treatment paradigm. Read more.
Dr. Tagawa discussed the evolution of therapeutic radiopharmaceuticals in prostate cancer, which he presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Read more.
The National Comprehensive Cancer Network and the Society of Nuclear Medicine and Molecular Imaging guidelines expanded to include the use of piflufolastat F 18 (Pylarify), along with all approved PSMA-PET imaging agents, for the selection of prostate cancer patients to receive PSMA-targeted radioligand therapy. Read more.